

Continuing Medical Education (CME) questions

Bortezomib, thalidomide, and dexamethasone in multiple myeloma

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 70% passing score) and earn continuing medical education (CME) credit, please go to <http://www.medscape.org/journal/blood>. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.org. If you are not registered on Medscape.org, please click on the “Register” link on the right hand side of the website. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to <http://www.ama-assn.org/ama/pub/category/2922.html>. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credits*™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet J-G, Decaux O, Dib M, Berthou C, Chaletex C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau J-L. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. *Blood*. 2011;118(22):5752-5758.

1. A 59-year-old man with untreated symptomatic multiple myeloma is about to undergo induction before high-dose therapy and autologous stem cell transplantation (ASCT). On the basis of the randomized trial by Dr Moreau and colleagues, which of the following statements about anticipated complete response (CR) rate with bortezomib/dexamethasone (VD) versus bortezomib and thalidomide plus dexamethasone (vtD) induction is *most likely* correct?

- The CR rate is likely to be significantly higher with VD
- The CR rate is likely to be significantly higher with vtD
- The CR rate in this study was 13% in the vtD arm and 12% in the VD arm
- The CR rate was the only end point in this study

2. The patient is started on vtD induction. On the basis of the randomized trial by Dr Moreau and colleagues, which of the following statements about anticipated CR plus very good partial response (VGPR) is *most likely* correct?

- After 4 cycles, the likelihood of achieving CR plus VGPR is about 25%
- After ASCT, the likelihood of achieving CR plus VGPR is about 50%
- Reduced doses of bortezomib and thalidomide are likely to yield higher VGPR rates compared with VD
- The study proved that progression-free survival was significantly better with vtD than with VD

3. On the basis of the randomized trial by Dr Moreau and colleagues, which of the following statements about anticipated safety of vtD induction in the patient is *most likely* correct?

- The likelihood of grade > 2 peripheral neuropathy is about 34%
- The likelihood of grade > 2 peripheral neuropathy is significantly less than with VD
- The likelihood of not being able to complete 4 cycles is about 25%
- The likelihood of not being able to complete stem cell collection is about 25%

Activity Evaluation (where 1 is strongly disagree and 5 is strongly agree)

1. The activity supported the learning objectives.
1 2 3 4 5
2. The material was organized clearly for learning to occur.
1 2 3 4 5
3. The content learned from this activity will impact my practice.
1 2 3 4 5
4. The activity was presented objectively and free of commercial bias.
1 2 3 4 5